AI-generated summary
This study protocol describes a planned double-blind, sham-controlled randomized trial in 130 patients with major depressive disorder and obstructive sleep apnoea who need CPAP. Participants will receive either active bright light therapy or sham light therapy during the first two weeks of CPAP use, with CPAP adherence as the primary outcome. The authors describe these as planned methods only, so no results are reported.
- Participants
- 130
- Who or what was studied
- Patients with comorbid major depressive disorder and obstructive sleep apnoea syndrome requiring CPAP therapy
- Wavelengths
- 500, 600 nm
- Limits stated in the abstract
- The abstract describes a study protocol only, so no outcomes or effects are reported.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on bmjopen.bmj.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 500 nm, 600 nm
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Bright light therapy, Sham, Wavelength, Lux, Trial registration, Primary outcome, Anxiety. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.